STOCK TITAN

PharmaDrug Announces Proposed Issuance of Debenture Units

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags

PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) announces the issuance of $414,523 in debenture units to replace outstanding secured convertible debentures. The new debentures will mature on September 30, 2025, and are convertible into common shares at $0.05 per share. The company will also issue 8,290,000 common share purchase warrants. No interest will be charged unless principal remains unpaid at maturity, triggering a 22% annual interest rate. The warrants allow holders to purchase shares at $0.05 for two years after issuance.

PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) annuncia l'emissione di $414,523 in unità di obbligazioni convertibili per sostituire le obbligazioni garantite convertibili in circolazione. Le nuove obbligazioni scadranno il 30 settembre 2025 e sono convertibili in azioni ordinarie a $0,05 per azione. L'azienda emetterà anche 8.290.000 diritti d'acquisto di azioni ordinarie. Non verrà addebitato alcun interesse a meno che il capitale non rimanga non pagato alla scadenza, attivando un tasso d'interesse annuo del 22%. I diritti consentono ai possessori di acquistare azioni a $0,05 per due anni dall'emissione.

PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) anuncia la emisión de $414,523 en unidades de obligaciones convertibles para reemplazar las obligaciones convertibles garantizadas pendientes. Las nuevas obligaciones vencerán el 30 de septiembre de 2025 y son convertibles en acciones ordinarias a $0.05 por acción. La compañía también emitirá 8,290,000 opciones de compra de acciones ordinarias. No se cobrará interés a menos que el capital permanezca impago al vencimiento, lo que activará una tasa de interés anual del 22%. Las opciones permiten a los tenedores comprar acciones a $0.05 durante dos años después de la emisión.

PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF)는 미지급 담보 전환 사채를 대체하기 위해 $414,523의 전환 사채 단위를 발행했음을 발표했습니다. 새로운 전환 사채는 2025년 9월 30일에 만기가 되며, 주당 $0.05로 보통주로 전환됩니다. 회사는 또한 8,290,000개의 보통주 매수 권리를 발행할 예정입니다. 원금이 만기 시까지 미납되지 않는 한 이자는 부과되지 않으며, 연간 22%의 이자율이 발생합니다. 이 권리는 발행 후 2년 동안 주식을 $0.05에 구매할 수 있게 해줍니다.

PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) annonce l'émission de $414,523 en unités d'obligations convertibles pour remplacer les obligations convertibles sécurisées en circulation. Les nouvelles obligations arriveront à échéance le 30 septembre 2025 et seront convertibles en actions ordinaires au prix de $0,05 par action. La société émettra également 8,290,000 bons de souscription d'actions ordinaires. Aucun intérêt ne sera facturé à moins que le capital ne reste impayé à l'échéance, ce qui déclenchera un taux d'intérêt annuel de 22%. Les bons permettent aux détenteurs d'acheter des actions à $0,05 pendant deux ans après l'émission.

PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) gibt die Ausgabe von $414,523 in Wandelanleihen bekannt, um ausstehende gesicherte Wandelanleihen zu ersetzen. Die neuen Anleihen laufen am 30. September 2025 aus und sind bei $0,05 pro Aktie in Stammaktien wandelbar. Das Unternehmen wird auch 8.290.000 Optionen zum Kauf von Stammaktien ausgeben. Es werden keine Zinsen berechnet, es sei denn, das Kapital bleibt bei Fälligkeit unbezahlt, wodurch ein jährlicher Zinssatz von 22% aktiviert wird. Die Optionen ermöglichen es den Inhabern, zwei Jahre nach der Emission Aktien zu einem Preis von $0,05 zu kaufen.

Positive
  • Debt restructuring extends maturity date to September 2025
  • No interest payments required unless principal remains unpaid at maturity
Negative
  • Issuance of $414,523 in new debt obligations
  • Potential dilution from 8,290,000 warrants and convertible debentures at $0.05 per share
  • High 22% interest rate penalty if principal not paid at maturity

Toronto, Ontario--(Newsfile Corp. - October 31, 2024) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics and naturally-derived approved drugs, is pleased to announce that it will be issuing $414,523 to replace currently outstanding secured convertible debentures and a total of 8,290,000 common share purchase warrants (each a "Warrant").

Each Debenture will mature on September 30, 2025 and will be convertible into common shares at a price of $0.05 (subject to adjustment). Each debenture will be secured by a general security agreement from the Company. The debentures are being issued to replace presently outstanding secured convertible debentures and outstanding interest thereon, which debentures had previously matured (but remained unpaid). There will be no interest payable on the debentures unless the principal amount is not paid at maturity, in which case the debentures will bear interest at a rate of 22% per annum. The Warrants to be issued in connection with the debentures will entitle the holder to acquire one common share at a price of $0.05 per share (subject to adjustment) for a period of two years following the issuance thereof.

About PharmaDrug Inc.
PharmaDrug is a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics and previously approved drugs. PharmaDrug owns 51% of Sairiyo Therapeutics ("Sairiyo"), a biotech company that specializes in researching and reformulating established natural medicines with a goal of bringing them through clinical trials and the associated regulatory approval process in the US and Europe. Sairiyo is currently developing its patented reformulation of cepharanthine, a drug that has shown substantial third party validated potential for the treatment of infectious disease and rare cancers. Sairiyo is also conducting R&D in the psychedelics space for the treatment of non-neuropsychiatric conditions. PharmaDrug also owns 100% of SecureDose Synthetics Inc. ("SecureDose"), a pharmaceutical research and development company focused on the development of synthetic formulations of currently existing drugs for potential commercialization and distribution.

For further information, please contact:

Robert J. Steen, Chairman and CEO
rob@pharmadrug.co
(416) 400-7086

Caution Regarding Forward-Looking Information:

THE CANADIAN SECURITIES EXCHANGE HAS NOT REVIEWED NOR DOES IT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results of the Company. Forward-looking statements in this press release relate to the anticipated timing of the issuance of the debentures and warrants referenced herein. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements.

Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking information. Such risks and other factors may include, but are not limited to: general business, economic, competitive, political and social uncertainties; general capital market conditions and market prices for securities; the actual results of the Company's future operations; competition; changes in legislation affecting the Company; the ability to obtain and maintain required permits and approvals, the timing and availability of external financing on acceptable terms; lack of qualified, skilled labour or loss of key individuals.

A description of additional risk factors that may cause actual results to differ materially from forward- looking information can be found in the Company's disclosure documents on the SEDAR+ website at www.sedarplus.ca. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. Accordingly, readers should not place undue reliance on forward-looking information. Readers are cautioned that the foregoing list of factors is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking information as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.

The Company's securities have not been registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), or applicable state securities laws, and may not be offered or sold to, or for the account or benefit of, persons in the United States or "U.S. Persons", as such term is defined in Regulations under the U.S. Securities Act, absent registration or an applicable exemption from such registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in the United States or any jurisdiction in which such offer, solicitation or sale would be unlawful.

Forward-looking information contained in this press release is expressly qualified by this cautionary statement. The forward-looking information contained in this press release represents the expectations of the Company as of the date of this press release and, accordingly, are subject to change after such date. However, the Company expressly disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/228534

FAQ

What is the maturity date for PharmaDrug's (LMLLF) new debenture units?

The new debenture units will mature on September 30, 2025.

What is the conversion price for PharmaDrug's (LMLLF) new debentures?

The debentures are convertible into common shares at a price of $0.05 per share, subject to adjustment.

How many warrants is PharmaDrug (LMLLF) issuing with the new debentures?

PharmaDrug is issuing 8,290,000 common share purchase warrants.

What is the interest rate on PharmaDrug's (LMLLF) new debentures if unpaid at maturity?

If the principal amount is not paid at maturity, the debentures will bear interest at 22% per annum.

PHARMADRUG INC

OTC:LMLLF

LMLLF Rankings

LMLLF Latest News

LMLLF Stock Data

1.53M
103.64M
0.88%
Drug Manufacturers - Specialty & Generic
Healthcare
Link
United States of America
Toronto